Torrent Pharma Slapped Rs 60.28 Lakh NPPA Notice for Alleged Overcharging

Written By :  Parthika Patel
Published On 2025-10-05 06:45 GMT   |   Update On 2025-10-05 06:45 GMT
Advertisement

New Delhi: Torrent Pharmaceuticals Limited has announced that it has received a demand notice from the National Pharmaceutical Pricing Authority (NPPA) imposing a penalty of Rs 60.28 lakh under the provisions of the Drug Price Control Order (DPCO) 2013 for alleged overcharging on two of its drug products.

In a regulatory filing dated 30th September 2025, the company stated that the demand notice, dated 24th September 2025, was issued by NPPA’s office in New Delhi and received by Torrent on 29th September 2025. The notice was issued under Para 15 of the DPCO 2013, which authorizes the authority to recover overcharged amounts from pharmaceutical manufacturers found selling scheduled drugs above government-fixed ceiling prices.

Advertisement

According to the company’s disclosure, the NPPA’s action pertains to alleged overcharging for two drugs during the periods May 2018 to July 2020 and August 2023, respectively. Torrent Pharma further clarified that after its internal review, it does not expect any material impact on its financials, operations, or other activities due to this notice.

Torrent Pharmaceuticals, headquartered in Ahmedabad, is a drug manufacturer known for its presence across therapeutic areas including cardiovascular, central nervous system, gastrointestinal, and anti-infective segments. The company has maintained that it will assess the notice appropriately while ensuring full regulatory compliance.

The communication was signed by Chintan M. Trivedi, Company Secretary of Torrent Pharmaceuticals Limited, and disclosed to both the stock exchanges in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News